SeaStar Medical Reports First Successful Treatment of Pediatric Patient with Hemophagocytic Lymphohistiocytosis (HLH) and Multi-Organ Failure with its SCD

Case report published in peer-reviewed journal, Pediatric Nephrology DENVER, CO and TAMPA, FL — SeaStar Medical, a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, and LMF Acquisition Opportunities, Inc. (NASDAQ: LMAO) (LMAO), a special purpose acquisition company, today announced that SeaStar Medical’s novel Selective Cytopheretic Device (SCD) […]

SeaStar Medical Submits Humanitarian Device Exemption Application to FDA for Use of Selective Cytopheretic Device in Children with Acute Kidney Injury

Application follows successful pilot study demonstrating the SCD was safe with probable clinical benefits for pediatric patients DENVER, CO and TAMPA, FL, July 20, 2022  — SeaStar Medical, a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, and LMF Acquisition Opportunities, Inc. (NASDAQ: LMAO) (LMAO), a special purpose […]

SeaStar Medical Announces Publication of Clinical Trial Results Demonstrating its SCD Significantly Lowered Mortality Rates among Critically Ill ICU COVID-19 Patients by Safely and Effectively Stopping Inflammation Causing Cytokine Storms

Results published in the Society of Critical Care Management’s journal, Critical Care Explorations DENVER, CO and TAMPA, FL, June 7, 2022 — SeaStar Medical, a medical technology company developing a platform therapy to reduce the consequences of hyperinflammation on vital organs, and LMF Acquisition Opportunities, Inc. (NASDAQ: LMAO) (LMAO), a special purpose acquisition company, today announced […]

SeaStar Medical Appoints Kevin Chung, MD as Chief Medical Officer

Dr. Chung is a renowned critical care physician, research and thought leader in extracorporeal life support therapies DENVER, CO and TAMPA, FL, May 24, 2022 — SeaStar Medical Inc., a medical technology company developing a platform therapy to reduce the consequences of hyperinflammation on vital organs, and LMF Acquisition Opportunities, Inc. (NASDAQ: LMAO) (LMAO), a […]

SeaStar Medical Granted FDA Breakthrough Device Designation for a Novel Immunomodulatory Therapy for Acute Kidney Injury Patients

Designation helps enable accelerated regulatory review of upcoming pivotal clinical trial for treatment in adult patients with acute kidney injury DENVER, CO and TAMPA, FL, May 03, 2022 — SeaStar Medical, a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, and LMF Acquisition Opportunities, Inc. (Nasdaq: LMAO) (“LMAO”), a special […]

SeaStar Medical to Become Publicly Listed on Nasdaq via Business Combination with LMF Acquisition Opportunities, Inc.

SeaStar Medical is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs Transaction to provide SeaStar with access to the capital markets, allowing it to accelerate the development and advancement of its proprietary and innovative immunomodulatory platform for pediatric and adult acute kidney injury (AKI) SeaStar Medical plans to […]

SeaStar Medical Presents Data from SCD 005 Clinical Study at the American Society of Nephrology (ASN) Kidney Week 2021 Annual Meeting

Results show promise for returning a dysregulated immune system to homeostasis in critically ill patients DENVER, CO, November 5, 2021— SeaStar Medical, a medical device company that has redefined how extracorporeal therapies may reduce excessive inflammation on vital organs, announced new data from its SCD 005 clinical study to evaluate the safety and feasibility of […]

SeaStar Medical Completes Enrollment of SCD 005 Trial to Evaluate Safety of Selective Cytopheretic Device (SCD) in AKI as well as ARDS Patients with COVID-19

Findings from the study in patients with AKI and/or ARDS with COVID-19 infection are expected later this year DENVER, JUNE 17, 2021 — SeaStar Medical, a medical technology company delivering novel therapeutic solutions to improve organ function, announced today that the company has completed enrollment of the SCD 005 study to evaluate the safety of […]

SeaStar Medical Announces Additions to Board of Directors

— Board members are industry leaders who will actively support company growth strategies — DENVER, Jan. 11, 2021 /PRNewswire/ — SeaStar Medical, a medical technology company delivering novel therapeutic immunomodulating solutions to improve organ function, announced today it has appointed Rick Barnett and Dr. Allan J. Collins to its board of directors, effective January 8, 2021.  “We are excited and honored to […]

SeaStar Medical Announces Positive Results from Pilot Clinical Study of the Selective Cytopheretic Device (SCD) in Pediatric Patients with Acute Kidney Injury

Study met primary and secondary endpoints related to survival and renal recovery at day 60. DENVER, Oct. 26, 2020 /PRNewswire/ — SeaStar Medical, a medical technology company delivering novel therapeutic immunomodulating solutions to improve organ function, today announced the results from the first every application of the Selective Cytopheretic Device (SCD) in pediatric patients with acute kidney injury […]